Core Viewpoint - The establishment of Peianmei (Zhejiang) Technology Co., Ltd. marks a significant collaboration between a technology company and the local government, aiming to innovate the healthcare service system through advanced technologies like medical models and brain-machine interfaces [1][2]. Group 1: Company Development - Peianmei was founded in September 2024 with a vision to integrate health management into daily life, supported by a diverse group of stakeholders including state-owned enterprises and universities [2][3]. - Within nine months, Peianmei has rapidly advanced in the health technology sector, establishing partnerships with various universities and institutions to develop innovative health solutions [3][4]. Group 2: Strategic Collaborations - Peianmei has formed strategic partnerships with institutions like Northwest A&F University and Yunnan University of Traditional Chinese Medicine to explore areas such as medical nutrition and traditional medicine integration [3][4]. - The company is also collaborating with Shenzen Yintong Health Industry Co., Ltd. and Capital Medical University to innovate in brain-machine interface technologies [4][6]. Group 3: Technological Innovations - Peianmei is developing a comprehensive health ecosystem that spans prevention, diagnosis, treatment, and rehabilitation, including initiatives like the "Health One Card" platform and the "Special Medical Food Research Laboratory" [5][6]. - The company aims to leverage artificial intelligence and big data to enhance healthcare delivery and management, addressing chronic diseases and improving patient outcomes [6][9]. Group 4: Alignment with National Strategy - Peianmei's initiatives align with national strategies such as the "Artificial Intelligence +" action plan, aiming to contribute to the "Healthy China" initiative by transforming health management practices [8][9]. - The company's ultimate goal is to make health management a daily reality for individuals, emphasizing preventive care and data-driven health solutions [9].

低升糖食品和医学营养减重食品已进入知名大型商超。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 据IPO早知道消息，近日，玛士撒拉（上海）生物科技有限公司（下称"玛士撒拉"）宣布完成近2亿 元B轮融资，由中金资本旗下基金、弘盛资本、弘晖基金联合领投，蜂巧资本、峰瑞资本跟投，凯乘 资本担任独家财务顾问。本轮融资将主要用于加速一系列医学营养品的开发，进一步扩大公司在特殊 医学营养、控能、DGI控糖三大业务板块的规模与领先优势。 玛士撒拉认为，中国的医学营养产业具备以下三个显著特征：1）市场需求庞大且尚未得到有效满 足。据统计，我国现存高血压患者2.45亿人、糖尿病患者1.3亿人、高脂血症患者2亿人，2024年度 实施手术总量达5280万例次，新增肿瘤患者近500万人。上述慢病人群及术后、肿瘤患者亟需专业 的医学营养产品及服务进行健康干预，但现有供给体系存在明显的缺口。尽管已获批的特医食品注册 证书超过200张，但产品同质化问题突出，其中肿瘤特定疾病全营养产品仅获批1项，难以满足患者 的实际临床需求。 2）产业良性发展亟需政策体系持续完善。鉴于医学营养直接关乎患者生命健康，行业对监管标准 ...